ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders |
On May31, 2017, we held our annual meeting of stockholders. A
total of 39,190,619 shares of our common stock were outstanding
as of April26, 2017, the record date for the annual meeting. Set
forth below are the matters acted upon at the annual meeting and
the final voting results on each matter as reported by our
inspector of elections.
Proposal One: Election of Directors
Our stockholders elected Mr.Joseph Jay P. Hagan, Dr.Troy Wilson
and Dr.KleanthisG. Xanthopoulos as members of our board of
directors as ClassIII directors for a three-year term. The
results of the vote were as follows:
|
Nominee |
For |
Withheld |
Broker Non-Votes |
|||
|
Joseph Jay P. Hagan |
9,535,918 | 7,280,212 | 13,895,696 | |||
|
Troy Wilson, Ph.D., J.D. |
10,806,499 | 6,009,631 | 13,895,696 | |||
|
Kleanthis G. Xanthopoulos, Ph.D. |
8,806,229 | 8,009,901 | 13,895,696 |
Proposal Two: Approval of the amendment to the Amended and
Restated 2014 Equity and Incentive Plan
Our stockholders approved the amendment of our Amended and
Restated 2014 Equity and Incentive Plan to increase the number of
shares of common stock approved for issuance under the plan by
700,000 shares. The results of the vote were as follows:
|
For |
Against |
Abstain |
Broker Non-Votes |
|||
|
11,958,696 |
4,817,079 | 40,355 | 13,895,696 |
Proposal Three: Ratification of Marcum LLP as our Independent
Registered Public Accountants for Fiscal 2017
Our stockholders ratified our selection of Marcum LLP as our
independent registered public accountants for our fiscal year
ending December31, 2017. The results of the vote were as follows:
|
For |
Against |
Abstain |
Broker Non-Votes |
|||
|
29,558,783 |
1,017,336 | 135,707 |
2
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
Exhibit Number |
Exhibit Description |
|
| 10.1 |
Zosano Pharma Corporation Amended and Restated 2014 Equity and Incentive Plan, as amended on May31, 2017. Filed herewith. |
3
About ZOSANO PHARMA CORPORATION (NASDAQ:ZSAN)
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.
